Carmat Investor Relations Material

Carmat SA is a French medical technology company that specializes in the development and manufacturing of advanced artificial heart systems. The company's flagship product is the Aeson, a biocompatible, fully implantable total artificial heart designed to provide a life-saving alternative for patients suffering from end-stage biventricular heart failure. Carmat's innovative heart prosthesis mimics the natural human heart's functions and aims to bridge the gap for patients awaiting heart transplants. Carmat SA is headquartered in Vélizy-Villacoublay, France, and its shares are listed on the Euronext Paris.